Send to

Choose Destination
Ann Med. 2010 Apr;42(3):231-40. doi: 10.3109/07853891003652534.

Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).

Collaborators (207)

Xu YS, Gu DF, Jia X, Chen J, Xu YH, Wang JH, Wang N, Zheng RP, Zhang SH, Liu CX, Sun LH, Zhao YC, Lin Y, Huang JB, Hu DY, Yang XC, Liu YZ, Gao MM, Zhang P, Deng CX, Liu Y, Li ZQ, Shi YQ, Hu TS, Chen YZ, Tan S, Zhao WR, Deng GL, Huang WJ, Zhang JC, Yu H, Shi QS, Wang XZ, Jiang B, Pan XR, Li L, Bu PL, Shu MQ, Xu QL, Zhang JH, Ding WH, Li L, Yang JJ, Su JL, Zhao WD, Liu X, Li LJ, Yang JF, Wang QS, Huang TG, Li LF, Zhou LJ, Guo JX, Li WH, Li ZP, Zhang XG, Peng XM, An YW, Shu J, Ma LT, Ge H, Zhang MJ, Lv ZR, Li JH, Yang JW, Zhang L, Cheng YL, Chen JG, Zhou CW, Zhang HH, Huang YL, Qu XF, Li JJ, Guo H, Wang GX, Hao SZ, Li SJ, Chang HS, Zhou SM, Liang HQ, Cao SJ, Liu JG, Yang J, Zhao MY, Lv Y, Xu SL, Wang SL, Zhao SP, Li XP, Luo XL, Li YP, Lei Y, Fan SQ, Wang LH, Zhao LJ, Zhao YC, Xue SW, Li J, Xu SY, Cao YG, Tong BG, Wang W, Xu SK, Chen HZ, Guo WL, Wang LJ, Xan XM, Li Y, Wei LP, Qiao L, Gao SS, Jing XF, Wang CH, Tang BX, Bai H, Li L, Liu Y, Li YP, Mei F, Yuan KZ, Zhang Y, Sun YR, Chen L, Xue SR, Wang JP, Li B, Liu XM, Shen LH, Liang JR, Zhang Y, Song YL, Sun YM, Wan Z, Xu YH, Zhang WJ, Mu RQ, Li KQ, Wei YP, Wang SM, Fan YJ, An KY, Guo J, Li AP, Zeng DY, Huo HY, Chen Y, Song LX, Jiang BQ, Guo DJ, Chen H, Li L, Yin YQ, Mao YM, Miao L, Guo YJ, Li SJ, Cui SS, Diao Q, You XM, Jiang B, Zhu LT, Liu JM, Fang L, Lin SG, Chen LY, Huang WH, Zheng ZG, Ke YN, Wang Y, Wang QS, Liang H, Jia RY, Wang T, Liu CX, Geng QJ, Duan BX, Fang CQ, Wang JY, Chang ZW, Qi Y, Wang X, He WS, Ye P, Liu YC, Li CY, Ye JJ, He BX, Zhang XY, Hong XF, Shi RG, Wei WL, Sun JJ, Li ZC, Zhang XJ, He P, Gao W, He YJ, Zhang HB, Li ND, He XN, Chen GL, Wang JL, Liang GF, Dai GZ, Wang Q, Jin HY, Wang S.

Author information

Department of Cardiology, Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P. R. China.



The lowering of cholesterol concentrations in individuals at high risk for cardiovascular disease improves clinical outcome. Xuezhikang has a marked impact on lipids.


In this randomized, double-blinded, placebo-controlled, parallel-group clinical trial, a total of 2704 hypertensive patients with previous myocardial infarction (MI) were assigned either to placebo (n = 1341) or to Xuezhikang (0.6 g twice daily, n = 1363) for an average of 4.5 years. The primary end-point was recurrent coronary events; the secondary end-point was all-cause mortality and other clinical events, including adverse effects.


There were no differences between the Xuezhikang and placebo group in base-line characteristics. However, Xuezhikang treatment reduced the incidence of coronary events by 43.0% (P = 0.02), deaths from coronary heart disease (CHD) by 30.0% (P < 0.01), and all-cause mortality by 35.8% (P = 0.001).


This study, for the first time, demonstrated that long-term Xuezhikang therapy resulted in significant reduction in cardiovascular events and death in Chinese hypertensive patients with previous MI in a safe manner.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center